Analysts Set Agenus Inc. (NASDAQ:AGEN) PT at $10.00

Agenus Inc. (NASDAQ:AGEN) has been assigned an average rating of “Hold” from the six analysts that are covering the company, MarketBeat Ratings reports. Five analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $10.00.

Separately, HC Wainwright restated a “neutral” rating on shares of Agenus in a research report on Wednesday, January 22nd.

Agenus Trading Down 6.6 %

Shares of AGEN stock opened at $2.41 on Friday. Agenus has a 1 year low of $2.37 and a 1 year high of $19.69. The firm’s fifty day simple moving average is $3.29 and its 200 day simple moving average is $3.95. The firm has a market capitalization of $56.54 million, a P/E ratio of -0.21 and a beta of 1.31.

Institutional Investors Weigh In On Agenus

Several hedge funds have recently made changes to their positions in AGEN. Corton Capital Inc. bought a new stake in shares of Agenus in the 4th quarter worth $36,000. Virtu Financial LLC purchased a new stake in shares of Agenus during the fourth quarter valued at $51,000. Apollon Wealth Management LLC bought a new stake in Agenus in the 4th quarter worth about $55,000. EP Wealth Advisors LLC purchased a new position in Agenus in the 3rd quarter worth about $55,000. Finally, Bank of Montreal Can bought a new position in Agenus during the 4th quarter valued at about $69,000. 61.46% of the stock is currently owned by institutional investors.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.